A simple, sensitive and convenient ion chromatography(IC) method was established for the simultaneous determination of twelve water-soluble inorganic anions(F -, Cl -, NO - 2, NO - 3, SO 2- 3, SO 2- 4, PO 3- 4), and f...A simple, sensitive and convenient ion chromatography(IC) method was established for the simultaneous determination of twelve water-soluble inorganic anions(F -, Cl -, NO - 2, NO - 3, SO 2- 3, SO 2- 4, PO 3- 4), and fifteen water-soluble organic ions(formate, acetate, MSA, oxalate, malonate, succinate, phthalates, etc.) in atmospheric aerosols. The linear concentrations ranged from 0.005 μg/m 3 to 500 μg/m 3(r = 0.999—0.9999). The relative standard deviation(RSD) were 0.43%—2.00% and the detection limits were from 2.7 ng/m 3 to 88 ng/m 3. The proposed method was successfully applied to the simultaneous determination of those inorganic ions and organic ions in PM 2.5 of Beijing.展开更多
Objective To observe the efficiency and safety of Thymosin-al for treatment of anti-HBe- and HBV DNA-positive chronic hepatitis B. Methods 56 patients were randomly divided into group A and B, and the baseline were co...Objective To observe the efficiency and safety of Thymosin-al for treatment of anti-HBe- and HBV DNA-positive chronic hepatitis B. Methods 56 patients were randomly divided into group A and B, and the baseline were comparable between group A and B (P>0.05). The patients in group A received Thymosin-α1 1.6 mg subcutaneous injection twice a week for 6 months, and the patients in group B received Interferon a 3-5 Mu each day for 15 days, then thrice a week for 6 months. All the patients were followed up for 6 months. Another 30 patients without Thymosin-al and Interferon alpha therapy as control were followed up for 12 months. Proportions of complete response at the end of therapy and follow-up were compared between group A, B and control. Complete response was defined as serum ALT normalization and HBV DNA loss. Results At the end of treatment, proportions of complete response were 30.8% (8/26) in group A and 46.7% (14/30) in group B, there was no evident difference between them (χ^2=1.47, P>0.05). At the end of follow-up, proportions of complete response were 42.3%% (11/26) in group A and 23.3%% (7/30) in group B, there was no evident difference between them (χ^2=2.29, P>0.05). At 6 months and 12 months of follow-up, proportions of complete response were 3.3% (1/30) and 3.3% (1/30). The proportion of complete response in group B at the end of treatment was significantly higher than that in control at 6 months of follow-up (χ^2=15.02, P<0.01), and the proportion of complete response in group A at the end of follow-up was significantly higher than that in control at 12 months of follow-up (χ^2=12.60, P<0.01). Unlike Interferon alpha, Thymosin-α1 was well tolerated in all patients, and no side effect was observed. Conclusions Thymosin-α1 for anti-HBe- and HBV DNA-positive chronic hepatitis B is effective and safe, and Thymosin-al can reduce HBV replication persistently in patients with anti-HBe-positive chronic hepatitis B.展开更多
文摘A simple, sensitive and convenient ion chromatography(IC) method was established for the simultaneous determination of twelve water-soluble inorganic anions(F -, Cl -, NO - 2, NO - 3, SO 2- 3, SO 2- 4, PO 3- 4), and fifteen water-soluble organic ions(formate, acetate, MSA, oxalate, malonate, succinate, phthalates, etc.) in atmospheric aerosols. The linear concentrations ranged from 0.005 μg/m 3 to 500 μg/m 3(r = 0.999—0.9999). The relative standard deviation(RSD) were 0.43%—2.00% and the detection limits were from 2.7 ng/m 3 to 88 ng/m 3. The proposed method was successfully applied to the simultaneous determination of those inorganic ions and organic ions in PM 2.5 of Beijing.
文摘Objective To observe the efficiency and safety of Thymosin-al for treatment of anti-HBe- and HBV DNA-positive chronic hepatitis B. Methods 56 patients were randomly divided into group A and B, and the baseline were comparable between group A and B (P>0.05). The patients in group A received Thymosin-α1 1.6 mg subcutaneous injection twice a week for 6 months, and the patients in group B received Interferon a 3-5 Mu each day for 15 days, then thrice a week for 6 months. All the patients were followed up for 6 months. Another 30 patients without Thymosin-al and Interferon alpha therapy as control were followed up for 12 months. Proportions of complete response at the end of therapy and follow-up were compared between group A, B and control. Complete response was defined as serum ALT normalization and HBV DNA loss. Results At the end of treatment, proportions of complete response were 30.8% (8/26) in group A and 46.7% (14/30) in group B, there was no evident difference between them (χ^2=1.47, P>0.05). At the end of follow-up, proportions of complete response were 42.3%% (11/26) in group A and 23.3%% (7/30) in group B, there was no evident difference between them (χ^2=2.29, P>0.05). At 6 months and 12 months of follow-up, proportions of complete response were 3.3% (1/30) and 3.3% (1/30). The proportion of complete response in group B at the end of treatment was significantly higher than that in control at 6 months of follow-up (χ^2=15.02, P<0.01), and the proportion of complete response in group A at the end of follow-up was significantly higher than that in control at 12 months of follow-up (χ^2=12.60, P<0.01). Unlike Interferon alpha, Thymosin-α1 was well tolerated in all patients, and no side effect was observed. Conclusions Thymosin-α1 for anti-HBe- and HBV DNA-positive chronic hepatitis B is effective and safe, and Thymosin-al can reduce HBV replication persistently in patients with anti-HBe-positive chronic hepatitis B.
